Novo Nordisk A/S reported flat sales and a decline in operating profit in 2018 as the impact of lower insulin prices in the US continued to weigh on the company’s financial results. But the outcome was better than the company’s own forecast, largely due to the strong performance of the glucagon-like peptide 1 (GLP-1) products Victoza and Ozempic for Type 2 diabetes and the obesity product Saxenda.
